SCHEDULE: Novo Holdings Drops Below 5% Stake in Edgewise Therapeutics
Schedule 13D Amendment
Novo Holdings A/S reports a decrease in beneficial ownership of Edgewise Therapeutics, Inc. common stock to below the 5% threshold due to dilution.
Summary
- Novo Holdings A/S now beneficially owns 5,350,000 shares of Edgewise Therapeutics, Inc. common stock.
- The current ownership stake represents approximately 4.98% of the issuer's outstanding shares.
- The change in percentage ownership is attributed to dilution from the issuer's share issuance rather than any sale or acquisition of shares by Novo Holdings.
- The reporting person is no longer required to maintain a Schedule 13D filing as they have fallen below the 5% beneficial ownership threshold.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting a change in ownership percentage due to dilution rather than a strategic divestment.
Positives
- The reporting person has not sold any shares, maintaining their total position of 5,350,000 shares.
Negatives
- The reporting person's percentage ownership has been diluted below the 5% reporting threshold.
Risks
- Dilution of ownership stake due to the issuer's capital structure changes.
Future Outlook
No specific future outlook provided; the filing is a technical disclosure regarding a change in ownership percentage.
Industry Context
StockSavvy.ai notes that this filing reflects standard regulatory compliance for institutional investors when their ownership percentage shifts due to corporate actions like equity offerings by the issuer.
Comparison to Industry Standards
- The filing adheres to standard SEC requirements for Schedule 13D amendments regarding changes in beneficial ownership.
Stakeholder Impact
- Shareholders should note the reduction in the reporting person's ownership percentage below the 5% threshold.
Next Steps
- The reporting person is no longer required to file Schedule 13D amendments for this issuer unless ownership increases above 5% again.
Key Dates
| Date | Description |
|---|---|
| 2021-03-31 | Original Schedule 13D filing date. |
| 2026-04-09 | Date of outstanding share count reported in issuer's proxy statement. |
| 2026-04-23 | Date of event requiring filing and date ownership fell below 5%. |
| 2026-04-27 | Date of current Amendment No. 6 filing. |
Keywords
Edgewise Therapeutics, Novo Holdings, Schedule 13D, Beneficial Ownership, Dilution, EWTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.